There are two distinct subtypes of lymphoma - Hodgkin lymphoma and a diverse group of non-Hodgkin lymphomas. According to the NCI Surveillance, Epidemiology, and End Results (SEER) Program statistical data, it is estimated that in 2024 there will be a total of 8,570 new cases and 910 estimated deaths attributed to Hodgkin lymphoma in the U.S. The observed incidence rates for this disease averaged 2.5 per 100,000 persons for years 2017-2021, and death rates were estimated at 0.3 per 100,000 persons for years 2018-2022. Non-Hodgkin lymphoma has been significantly more prevalent with 80,620 estimated new cases and 20,140 estimated deaths in 2024. Annual observed incidence estimated was 18.6 per 100,000 for years 2017-2021, and death rate was 5.0 per 100,000 for years 2018-2022. Despite favorable trends, lymphomas remain a serious medical problem affecting individuals of all ages.
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
